It's not too early to start planning for Wi-Fi 8. New features include non-primary channel access, seamless mobility domain ...

Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans ...

Strengthened balance sheet and advancing clinical pipeline with multiple catalysts expected through 2027SOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ( ...

As competition in the weight loss drug market progressively intensifies, the latest Phase III clinical data disclosed by BrightGene Bio-Medical (688166.SH) for BGM0504 has reignited market attention.

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) Q1 net sales of $106.7 million, ...

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late ...

Indian researchers accelerate pharma–nutraceutical integration to transform metabolic health: Nandita Vijayasimha, Bengaluru Tuesday, May 5, 2026, 08:00 Hrs [IST] India’s rese ...

(“Encoded”), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, ...

Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patient ...

aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C ...

Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, today announced a ...

The European Commission said that it runs afoul of the EU single market, violates existing e-commerce regulations and is otherwise "incompatible with Union law." ...